PubRank

Kelly L Warfield

Author PubWeight™ 55.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010 3.25
2 Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006 2.56
3 Rotavirus antigenaemia and viraemia: a common event? Lancet 2003 2.51
4 Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror 2006 2.43
5 Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A 2005 2.35
6 Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 2012 2.00
7 Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008 1.78
8 VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006 1.63
9 Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004 1.58
10 Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005 1.44
11 Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis 2008 1.30
12 Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009 1.26
13 Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008 1.23
14 Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology 2010 1.23
15 Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One 2012 1.20
16 Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods 2005 1.16
17 Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol 2013 1.16
18 Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004 1.13
19 Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 2008 1.10
20 Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol 2013 1.10
21 Mouse models for filovirus infections. Viruses 2012 1.07
22 Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun 2005 1.06
23 Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem 2012 1.04
24 An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res 2013 1.04
25 Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010 1.02
26 Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 2005 1.01
27 The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol 2004 1.01
28 Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J Virol 2011 1.01
29 Active viremia in rotavirus-infected mice. J Virol 2006 1.00
30 Early response to rotavirus infection involves massive B cell activation. J Immunol 2002 0.98
31 Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process. J Virol 2011 0.96
32 Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection. Cell Host Microbe 2009 0.94
33 Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008 0.93
34 NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol 2007 0.92
35 Involvement of vacuolar protein sorting pathway in Ebola virus release independent of TSG101 interaction. J Infect Dis 2007 0.91
36 Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model. PLoS One 2013 0.88
37 Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother 2015 0.86
38 AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med 2015 0.83
39 Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity. J Virol 2008 0.82
40 Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles. J Pharm Sci 2011 0.80
41 Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virol J 2009 0.79
42 Induced IL-10 splice altering approach to antiviral drug discovery. Nucleic Acid Ther 2014 0.76
43 Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog 2015 0.75
44 Research and analytics in combat trauma care: converting data and experience to practical guidelines. Surg Clin North Am 2012 0.75